UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 22, 2019
MYND ANALYTICS, INC.
(Exact name of Company as specified in its
charter)
Delaware
|
|
001-35527
|
|
87-0419387
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File No.)
|
|
(I.R.S. Employer
Identification No.)
|
26522 La Alameda
Mission Viejo, CA 92691
(Address of principal executive offices)
(949) 420-4400
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
Warrants to Purchase Common Stock
|
MYND
MYNDW
|
The Nasdaq Stock Market LLC
The Nasdaq Stock Market LLC
|
Item 1.01 Entry into Material Definitive
Agreement.
On May 22, 2019, MYnd Analytics, Inc. (the
“
Company
”) entered into a fee agreement (the “
Fee Agreement
”) with T.R. Winston & Company,
LLC (the “
Placement Agent
”) relating to the Company’s registered direct offering of common stock (the
“
Offering
”) to select investors (the “
Investors
”). Pursuant to the Fee Agreement, the Company
agreed to pay the Placement Agent (i) a cash fee of 7.0% of the gross proceeds from the Offering raised from Investors, and (ii)
warrants to purchase shares of common stock equal to 7.0% of the aggregate number of shares issued to Investors in the Offering.
In addition, on May 22, 2019, the Company and the Investors
entered into a securities purchase agreement (the “
Securities Purchase Agreement
”) relating to the issuance
and sale of shares of common stock. The purchase price per share for each share offered to the Investors is $1.02. The aggregate
gross proceeds of the Offering is approximately $2,832,020, for an aggregate of 2,776,491 shares of common stock.
The net proceeds to the Company from the Offering, after deducting
Placement Agent fees and the Company’s estimated offering expenses, are expected to be approximately $2,533,779. The Offering
is expected to close on or before May 28, 2019, subject to the satisfaction of customary closing conditions.
The common stock is registered under the Securities Act of 1933,
as amended, on the Company’s Registration Statement on Form S-3 (Registration No. 333-223203), previously filed with the
Securities and Exchange Commission and declared effective on June 29, 2018.
The foregoing description of the Fee Agreement and the Securities
Purchase Agreement are subject to, and qualified in their entirety by, the documents attached hereto as Exhibits 1.1 and 10.1,
respectively, and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On May 23, 2019, the Company issued a press release with respect
to the information set forth above. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The disclosure in this Item 7.01 (including the exhibit) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor
shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended,
or the Exchange Act, except to the extent, if any, expressly set forth by specific reference in such filing.
Item 9.01(d). Financial Statements and Exhibits.
(d) Exhibits
.
IMPORTANT INFORMATION ABOUT THE TRANSACTIONS WILL BE FILED
WITH THE SEC
This communication is being made in respect of the proposed
business combination involving MYnd and Emmaus Life Sciences, Inc. (“Emmaus”). In connection with the proposed transaction,
MYnd and Emmaus have filed documents with the SEC, including the filing by MYnd of a Registration Statement on Form S-4 containing
a Joint Proxy Statement/Prospectus, filed on February 13, 2019, and each of MYnd and Emmaus plan to file with the SEC other documents
regarding the proposed transactions. INVESTORS AND SECURITY HOLDERS OF MYND AND EMMAUS ARE URGED TO CAREFULLY READ THE JOINT PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC BY MYND AND EMMAUS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT
THE PROPOSED TRANSACTIONS. Investors and security holders may view these documents and other documents filed with the SEC at the
SEC’s web site at www.sec.gov and by contacting MYnd Investor Relations at mynd@crescendo-ir.com. Investors
and security holders may view the documents filed with the SEC on MYnd’s website at www.myndanalytics.com or through
the SEC’s website at www.sec.gov. Investors and security holders are urged to read the Joint Proxy Statement/ Prospectus
and other documents filed with the SEC before making any voting or investment decision in connection with the proposed transactions.
PARTICIPANTS IN THE SOLICITATION
MYnd, Emmaus and their respective directors and executive officers
may be deemed participants in the solicitation of proxies with respect to the proposed transaction. Information regarding the
interests of these directors and executive officers in the proposed transaction has been included in the Joint Proxy Statement/Prospectus
described above. Additional information regarding the directors and executive officers of MYnd is also included in MYnd’s
proxy statement for its 2018 Annual Meeting of Shareholders, which was filed with the SEC on March 1, 2018, as updated in MYnd’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2018, and additional information regarding the directors and
executive officers of Emmaus is also included in Emmaus’ proxy statement for its 2018 Annual Meeting of Stockholders, which
was filed with the SEC on August 23, 2018. Additional information regarding the interests of those participants and other persons
who may be deemed participants in the transaction may be obtained by reading the Joint Proxy Statement/Prospectus regarding the
proposed transaction.
NO OFFERS OR SOLICITATIONS
This communication shall not constitute an offer to sell or
the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements
of Section 10 of the Securities Act.
CAUTIONARY NOTE
REGARDING FORWARD-LOOKING STATEMENTS
This Current Report on Form 8-K contains “forward-looking”
statements within the meaning of the Private Securities Litigation Reform Act of 1995, giving MYnd’s and Emmaus’ expectations
or predictions of future financial or business performance or conditions, including, without limitation, statements related to
(i) market opportunities for certain of the Company’s products, (ii) general market trends in mental health and payor coverage,
(iii) the ability of MYnd’s products to successfully produce objective data, improve efficiency in the treatment of depression
and other mental health and psychiatric illnesses, recognize patterns, predict outcomes and personalize medicine, improve patient
outcomes or reduce healthcare costs, (iv) statements relating to the Agreement and Plan of Merger dated as of January 4, 2019,
by and among the Company, the Company’s wholly owned subsidiary, Athena Merger Subsidiary, Inc., and Emmaus (the “Merger
Agreement”), (v) the transactions contemplated by the Merger Agreement including but not limited to the Merger (as defined
in the Merger Agreement) and (vi) MYnd’s or the combined company’s future financial condition, performance and operating
results, strategy and plans. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which
change over time. Forward-looking statements speak only as of the date they are made and MYnd and Emmaus assume no duty to update
forward-looking statements.
In addition to factors previously disclosed in MYnd’s
and Emmaus’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”) and those identified elsewhere
in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking
statements and historical performance: the ability of MYnd to meet the closing conditions to the Merger, including requisite approval
by MYnd’s and Emmaus’ stockholders on a timely basis or at all; delay in closing the Merger; the ability to effect
the proposed spin-off; adverse tax consequences to shareholders of the proposed spin-off; disruption following the Merger; the
ability of MYnd’s products to successfully produce objective data; the ability of MYnd’s products to improve efficiency
in the treatment of depression and other mental health and psychiatric illnesses; the ability of MYnd’s products to recognize
patterns, predict outcomes and personalize medicine; the ability of MYnd’s products to improve patient outcomes and to reduce
healthcare costs; and the availability and access, in general, of funds to fund operations and necessary capital expenditures.
Other risks and uncertainties are more fully described in MYnd’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2018, and Emmaus’ Annual Report on Form 10-K for the year
ended December 31, 2017, each filed with the SEC, and in other filings that MYnd or Emmaus makes and will make with the SEC in
connection with the proposed transactions, including the Joint Proxy Statement/Prospectus described herein under “Important
Additional Information About the Transaction Will be Filed with the SEC.” Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in
this Current Report on Form 8-K and the exhibits attached hereto speak only as of the date stated herein, and subsequent events
and developments may cause MYnd’s or Emmaus’ expectations and beliefs to change. While MYnd or Emmaus may elect to
update these forward-looking statements publicly at some point in the future, each of MYnd and Emmaus specifically disclaims any
obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing MYnd’s or Emmaus’ views as of any date after the date stated herein..
The Company’s actual results, performance or achievements could differ materially from those contemplated, expressed or implied
by the forward-looking statements.
SIGNATURES
Pursuant to the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MYnd Analytics, Inc.
|
|
|
|
By:
|
/s/ Donald D’Ambrosio
|
May 23, 2019
|
|
Donald D’Ambrosio
|
|
|
Chief Financial Officer
|
MYnd Analytics, Inc. (NASDAQ:MYND)
Historical Stock Chart
From Mar 2024 to Apr 2024
MYnd Analytics, Inc. (NASDAQ:MYND)
Historical Stock Chart
From Apr 2023 to Apr 2024